A Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Systemic Juvenile Idiopathic Arthritis (SKYPS)

← catalyst calendar

NCT02991469 · readout in 560 d

Sponsored by Sanofi (industry) · SNY — their whole pipeline →. With Regeneron Pharmaceuticals.

Phase

Phase 2

Status

Recruiting

Study type

Interventional

Design

Na · None · Treatment

Enrollment

51estimated

Sites

Countries

Argentina, Canada, Finland +9

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2018-08-09

actual

When the study began enrolling

Primary completion

2028-03-01

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2031-01-17

estimated

The whole study's end, after follow-up

First posted

2016-12-13

estimated

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-05-22

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Juvenile Idiopathic Arthritis

Intervention

Drug: Sarilumab SAR153191 (REGN88)

Primary outcomes

what the primary-completion date above is the date OF

Assessment of PK parameter: maximum serum concentration observed (Cmax)

measured Up to Week 12

Assessment of PK parameter: Area under the serum concentration versus time curve calculated using the trapezoidal method during a dose interval (AUC0-t)

measured Up to Week 12

Assessment of PK parameter: Concentration observed before treatment administration during repeated dosing (Ctrough)

measured Up to Week 12

Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed